Results 11 to 20 of about 45,621 (284)

Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group [PDF]

open access: yesOman Medical Journal, 2013
Objective: Different findings indicate that CYP2C plays a clinical role in determining interindividual and interethnic differences in drug effectiveness. The ethnic differences in the frequency of CYP2C19 mutant alleles continue to be a significant study
Robabeh Ghiyas Tabari   +4 more
doaj   +4 more sources

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update [PDF]

open access: yesClinical pharmacology and therapy, 2017
CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (e.g., nortriptyline and desipramine) and others by both polymorphic enzymes (e.g., amitriptyline,
J. Hicks   +13 more
semanticscholar   +3 more sources

Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole

open access: yesClinical Pharmacokinetics, 2023
Background and Objective CYP2C19-mediated drug interactions of acid-reducing agents are clinically important given the high possibility of concomitant administration with CYP2C19 substrates.
Eunsol Yang   +3 more
semanticscholar   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors [PDF]

open access: yesClinical pharmacology and therapy, 2015
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety.
J. Hicks   +15 more
semanticscholar   +3 more sources

Economic evaluations of pharmacogenetic and pharmacogenomic screening tests : a systematic review : second update of the literature [PDF]

open access: yes, 2016
Objective : Due to extended application of pharmacogenetic and pharmacogenomic screening (PGx) tests it is important to assess whether they provide good value for money. This review provides an update of the literature. Methods : A literature search was
Annemans, Lieven   +7 more
core   +16 more sources

The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank

open access: yesPharmaceuticals, 2023
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly used psychopharmaceutical treatment for major depressive disorder (MDD), but individual responses to SSRIs vary greatly.
Win Lee Edwin Wong   +7 more
semanticscholar   +1 more source

Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution Genome evolution and evolutionary systems biology [PDF]

open access: yes, 2014
© 2014 Janha et al.; licensee BioMed Central Ltd.Background: Cytochrome P450 CYP2C19 metabolizes a wide range of pharmacologically active substances and a relatively small number of naturally occurring environmental toxins.
Janha, RE   +5 more
core   +5 more sources

Distribution of a novel CYP2C haplotype in Native American populations

open access: yesFrontiers in Genetics, 2023
The CYP2C19 gene, located in the CYP2C cluster, encodes the major drug metabolism enzyme CYP2C19. This gene is highly polymorphic and no-function (CYP2C19*2 and CYP2C19*3), reduced function (CYP2C19*9) and increased function (CYP2C19*17) star alleles ...
Vanessa Câmara Fernandes   +4 more
doaj   +1 more source

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19

open access: yesTranslational Psychiatry, 2021
Extensive migration has led to the necessity of knowledge regarding the treatment of migrants with different ethnical backgrounds. This is especially relevant for pharmacological treatment, because of the significant variation between migrant groups in ...
A. Koopmans   +4 more
semanticscholar   +1 more source

CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings

open access: yesJournal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2022
Background Studies have demonstrated increased risk of major atherothrombotic events in CYP2C19 loss‐of‐function (LOF) variant carriers versus non‐carriers treated with clopidogrel after percutaneous coronary intervention (PCI).
A. Beitelshees   +23 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy